FDA calendar · March 2024 · built from SEC filings
PDUFA dates March 2024: FDA calendar and catalysts.
Updated Snapshot 20261116T222116ZBuilt
4 PDUFA dates fell in March 2024: LCTX (Mar 2024), HETLIOZ® (March 4), MDGL (March 14), RCKT (March 31). The FDA calendar also recorded 56 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
PDUFA dates in March 2024
4 PDUFA target action dates in March 2024, soonest first, each linked to the SEC filing or FDA page that disclosed it. Data as of .
2 more milestones are guided to a half-year or full-year window, or estimated from ClinicalTrials.gov primary completion dates, that overlaps March 2024. They are on each drug page and in the calendar API.
Questions
What PDUFA dates are in March 2024?
4 PDUFA dates fell in March 2024: LCTX (Mar 2024), HETLIOZ® (March 4), MDGL (March 14), RCKT (March 31). The FDA calendar also recorded 56 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
Can these dates change?
Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.
Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.